Get the Stockscreener App
0.7874
4.59%
0.0331
Tenaya Therapeutics Inc stock is traded at $0.7874, with a volume of 3.18M.
It is up +4.59% in the last 24 hours and up +19.53% over the past month.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
See More
Previous Close:
$0.7543
Open:
$0.7549
24h Volume:
3.18M
Relative Volume:
0.76
Market Cap:
$170.82M
Revenue:
-
Net Income/Loss:
$-90.60M
P/E Ratio:
-1.2562
EPS:
-0.6268
Net Cash Flow:
$-68.88M
1W Performance:
+19.48%
1M Performance:
+19.53%
6M Performance:
-41.56%
1Y Performance:
+69.04%
1-Day Range:
$0.75
$0.82
1-Week Range:
$0.6666
$0.82
52-Week Range:
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.7872 | 163.68M | 0 | -90.60M | -68.88M | -0.6268 |
VRTX
Vertex Pharmaceuticals Inc
|
425.19 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.55 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.76 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.29 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.86 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Tenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 4.4%Here's Why - MarketBeat
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN
Tenaya to present TN-401 gene therapy trial data at ASGCT - Investing.com UK
Tenaya Therapeutics to present new clinical data from RIDGE-1 Phase 1b/2 TN-401 trial at ASGCT - Traders Union
Tenaya to present TN-401 gene therapy trial data at ASGCT By Investing.com - Investing.com South Africa
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 - The Manila Times
Tenaya to show 1-year heart gene therapy data in late-breaking talk - Stock Titan
Tenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20 - MSN
TNYA.O Technical Analysis & Stock Price Forecast - Intellectia AI
TNYA (Tenaya Therapeutics) posts slight Q4 2025 EPS beat, but shares drop 5.2 percent on soft investor sentiment.Trending Social Stocks - Xã Thanh Hà
TNYA Tenaya Therapeutics Inc. shares gain over 4 percent after Q4 2025 earnings narrowly top analyst consensus estimates.Crowd Consensus Signals - UBND thành phố Hải Phòng
TNYA.O PE Ratio & Valuation, Is TNYA.O Overvalued - Intellectia AI
TNYA Should I Buy - Intellectia AI
TNYA News & Events - Intellectia AI
Does Tenaya Therapeutics (TNYA) stock carry significant risk | Q4 2025: Better Than ExpectedAI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
When Will Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Become Profitable? - Yahoo Finance
TNYA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
When to Sell Tenaya Therapeutics (TNYA) Stock (Smart Money Exits) 2026-04-16Social Trading Insights - Cổng thông tin điện tử tỉnh Tây Ninh
Tenaya Therapeutics (TNYA) seeks approval for larger equity plan and director slate - Stock Titan
[ARS] Tenaya Therapeutics, Inc. SEC Filing - Stock Titan
Tenaya Therapeutics Receives 'Moderate Buy' Rating from Brokerages - National Today
Tenaya Therapeutics (TNYA) Stock Analysis Report | Financials & Insights - Benzinga España
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
TNYA Stock Price, Quote & Chart | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
If You Invested $1,000 in Tenaya Therapeutics, Inc. (TNYA) - Stock Titan
William Blair analysts confident on Tenaya Therapeutics (TNYA) product pipeline - MSN
Revenue Check: Is Tenaya Therapeutics Inc in a long term uptrendTreasury Yields & Community Consensus Stock Picks - baoquankhu1.vn
Investor Mood: Is Tenaya Therapeutics Inc stock a value trap2026 Levels & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Tenaya Therapeutics (NASDAQ:TNYA) Shares Down 5%Here's What Happened - MarketBeat
Is Tenaya Therapeutics (TNYA) Stock Competitive Now | Price at $0.66, Down 4.98%Crowd Risk Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):